Fig. 2

Sensitivity and specificity of AVEC: anti-HER-2 × HBsAg in targeting ovarian cancer cells. (a) The ovarian cancer cells from cultures (OV90, TOV112, SK-OV-30), from the ovarian epithelial cancers of the patients (001-0012), human ovary surface (HOSE), human artery endothelial (HAE) cells were labeled with trastuzumab, anti-HER 2001 × anti-HBsAg, anti-HER-2004 × anti-HBsAg, and relevant isotype antibodies rendered superparamagnetic. Antibodies labeling the cells were changing the cells’ magnetic properties, which were measured with nuclear magnetic resonance (NMR). The assays were repeated four times. The data presented are representative for all acquired. The changes in the length of T1 resulted from the changes in magnetic resonance, which were altered by presence of superparamagnetic antibodies and were proportional to the numbers of antibodies attached to the labeled cells. With the same number of cells in each batch, the relaxivity changes were directly proportional to the numbers of cell receptors displayed by the cells. Therefore, they facilitated comparisons of sensitivity of labeling between the cells, while being pursued with different antibodies. The OV90, TOV112, and SKOV3 cells were labeled with trastuzumab, anti-HER-2 biosimilars, and AVEC: anti-HER-2 × HBsAg at the statistically significant superiority over those labeled with the isotype antibodies and isotype-based AVEC. The control HOSE and HAE cells were labeled at the same levels as the isotype antibodies. (b) The ovarian cancer ascites cells from the patients vHBV001-012 were labeled with the same superparamagnetic antibodies, followed by the measurement of relaxivities, as outlined for cultured cells in a. The ovarian epithelial cancer ascites cells were all showing high numbers of the HER-2 receptors specifically labeled by the tested antibodies. Measurements of the relaxivities demonstrated statistically significant difference in the numbers of receptors on the ovarian epithelial cancer ascites cells over HOSE and HAE. Measurements of the relaxivities demonstrated statistically significant difference attained by labeling with the anti-HER-2 antibodies and AVEC over the relevant isotypes. The assays were repeated four times. The data presented are representative for all acquired (i isotype antibody). (c–f) The ovarian epithelial cancer cells from cultures (OV90, TOV112, SK-OV-30) and (g–j) the ovarian cancer cells from the patients 001-0012, (k–n) human ovary surface epithelial (HOSE), human artery endothelial (HAE) cells were labeled with trastuzumab (c, g), anti-HER-2001 × HBsAg, anti-HER-2004 × HBsAg (h, k), and relevant isotype antibodies (k–n) rendered fluorescent to acquire fluorescent properties. They were studied with flow cytometry (FCM) and fluorescent activated cell sorting (FACS). The fluorescently labeled ovarian cancer cultured cells facilitated their high counts and efficient sorting. The counts from the cells labeled with therapeutic antibodies and AVEC were statistically significantly higher than the cells labeled with the relevant isotype antibodies. These counts were statistically significantly higher than of HOSE and HAE cells. The assays were repeated four times. The data presented are representative for all acquired (i isotype antibody)